L'Oréal is doubling down on beauty, and the stakes are high! The French cosmetics giant is increasing its investment in Galderma, a leading dermatology company, from an initial 10% to a significant 20% stake. This move signals L'Oréal's strong commitment to the rapidly expanding aesthetics market. But what does this mean for the future of beauty? Let's dive in.
This strategic acquisition involves purchasing shares from a consortium led by EQT, including entities like Sunshine SwissCo GmbH and Abu Dhabi Investment Authority, for an undisclosed sum. L'Oréal CEO Nicolas Hieronimus highlights that aesthetics is a key area for their core business, and their initial investment in Galderma has already proven successful.
Galderma, originally co-founded by L'Oréal, is experiencing impressive growth under CEO Flemming Ørnskov. With a focus on innovation and consumer-focused approaches, Galderma is rapidly becoming a dermatology powerhouse. This increased investment from L'Oréal further validates their direction and potential for future value creation.
But here's where it gets interesting: While L'Oréal's stock dipped slightly, Galderma's stock saw a positive surge upon the announcement. The transaction, expected to close by the first quarter of 2026, will be funded using L'Oréal's available cash and credit lines.
The dermatological beauty market is booming. The global injectable aesthetics market was valued at $9.45 billion in 2023 and is projected to reach $18.12 billion by 2032, demonstrating a compound annual growth rate of 7.5%. This growth underscores the strategic importance of L'Oréal's investment. L'Oréal has stated that it will continue to support Galderma's strategy and independence.
Controversially, analysts are speculating about L'Oréal's potential for full control over Galderma's ex-Therapeutic Derm franchise. Some believe L'Oréal may not be interested in Galderma's prescription drug business.
As part of this expanded partnership, Galderma's board of directors will consider appointing two non-independent board candidates from L'Oréal, replacing the EQT-led consortium starting from the 2026 annual general meeting.
Galderma's history is intertwined with L'Oréal's. Established in 1981 as a joint venture, Galderma has evolved significantly. Nestlé acquired L'Oréal's stake in 2014, and in 2019, EQT Partners and ADIA acquired the company, which was then rebranded as Galderma. Today, Galderma operates in approximately 90 countries with brands like Cetaphil, Azzalure, and Dysport.
Galderma's initial public offering on the SIX Swiss Exchange in Zurich on March 22, 2024, was a resounding success, with its stock soaring 20.75% on its first day of trading. Since its public offering, Galderma's stock has risen by 158.9%.
The initial partnership, announced on August 5, 2024, included a new strategic scientific collaboration leveraging Galderma's expertise and L'Oréal's knowledge. This partnership has focused on a diagnostic research project aimed at developing tools for product development.
Galderma's transformation is notable, growing from a 1.6-billion-euro company to a 4.4-billion-euro company in 2024. The company has shifted from primarily therapeutic to a pure-play dermatology concern.
In March 2023, L'Oréal rebranded its Active Cosmetics division to Dermatological Beauty, aiming to be the leading partner to dermatologists worldwide. This division, which includes brands like CeraVe and La Roche-Posay, was the group's second-fastest-growing division.
L'Oréal's increased interest in Galderma is a reflection of the dermatological beauty market's strength and the potential synergies. Hieronimus highlighted the investment's relevance, especially considering L'Oréal's strong relationships with 200,000 dermatologists globally.
What do you think? Will this increased investment solidify L'Oréal's position in the beauty market? Do you foresee any potential challenges or opportunities arising from this partnership? Share your thoughts in the comments below!
